



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the use of Rituximab in Low-Grade Non-Hodgkin's Lymphoma  
(NHL)  
Capital District Health Authority/*Cancer Care Nova Scotia***

**Approved Use:**

**Rituximab:** In **combination with chemotherapy (i.e. R-CVP or R-CHOP)** in patients who have documented evidence of CD20 positive low-grade NHL, with an ECOG performance status of 0-2, and choose to receive combination chemotherapy.

This includes:

- Patients who have **not** previously received therapy for low-grade NHL and who are **appropriate candidates** for chemotherapy should receive this chemotherapy (i.e. CVP or CHOP) in combination with rituximab.
- Patients **who have** previously received therapy for low-grade NHL and have **never** received rituximab and who are **appropriate candidates** for chemotherapy should receive this chemotherapy in **combination with rituximab**.
- Patients **who have** previously received rituximab and who have achieved a response of at least **one year's duration** to the last rituximab administration and who are appropriate candidates for chemotherapy should receive this chemotherapy in **combination with rituximab**.
- The combination trials suggest improved benefit over single agent rituximab. Re-treatment is limited to those patients who have achieved a response of at least **one year's duration** and should receive this therapy in **combination with chemotherapy** (if appropriate candidate for chemotherapy).